17,261 trials
Prostate Cancer Recurrent
Primary: Participants With Greater Than or Equal to 50% Induction in Serum PAR4 Levels — 11 Participants
Pneumonitis · SARS-CoV Infection
Primary: Number of Serious Adverse Events Relative to Treatment Group — 1; 3; 0 participants
Severe Haemophilia A
Primary: Number of Participants With Treatment Emergent Adverse Events — 1; 1; 6; 7 Participants
Alopecia Areata · Alopecia · Alopecia Totalis
Primary: Number of Treatment Emergent Adverse Events — 27 Participants
Carcinoid Syndrome · Metastatic Nonfunctional Well Differentiated Neuroendocrine Neoplasm
Primary: The Proportion of Patients Who Achieved SUVmax Reduction of 20% or More Between Baseline and Follow up Scan — 0 Proportion of participants
SARS-CoV Infection · Covid19
Primary: Number of Participants With Solicited Local and Systemic Adverse Events (AE's) — 71; 32; 32; 28 participants
Glioblastoma Multiforme
Primary: Maximum Tolerated Dose (MTD) of DSF (Dose-escalation Phase Only) — 375 mg
Major Depressive Disorder · Alcohol Use Disorder
Primary: Number of Participants With 50% or Greater Improvement in MADRS Scores From Baseline — 15; 9; 13 Participants
Labor Onset and Length Abnormalities
Primary: Cervical Ripening Rate, Measured by Bishop Score - Slope — 0.86; 0.81; 0.78; 0.62 Slope (Bishop Score/day)
Cigarette Smoker · Current Smoker · Former Smoker
Primary: Diagnostic Performance Metrics (Sensitivity, Specificity, PPV, NPV, and Accuracy) of Ultrasonography and Capnography for Malignant Lung Nodules — 100; 70; 100; 100…
Growth Hormone Deficiency (GHD)
Primary: Annualized Height Velocity — 7.99; 7.46; 7.12; 4.63 cm/year
Guillain-Barré Syndrome (GBS)
Primary: Guillain Barré Syndrome Disability Score (GBS DS) - Time to Improve by at Least 1 Grade — 6.0 days
Ocular Graft Versus Host Disease
Primary: Overall Response Rate — 3; 6 eyes — p=0.375
Spinal Muscular Atrophy
Primary: Number of Participants With Dose Limiting Toxicities (DLT) in Part 1 - Safety Analysis Set (SAS) — 0; 0; 0; 0 Participants
Diabetic Retinopathy
Primary: Percentage of Participants With Improvement in DRSS by ≥ 2 Steps at 48 Weeks of Treatment in the Study Eye — 0.0; 1.9 percentage of participants